Isabel Arrillaga‐Romany

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.4K citations

Medicine, Immunology, Oncology +17

Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells

Philipp Karschnia, Justin T. Jordan, Deborah Forst et al. · Blood · 2019 · 347 citations · Full text

Life Sciences, Immunology, Neurology +16

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen et al. · Nature Medicine · 2023 · 219 citations · Full text

Medicine, Oncology, Pharmacology +17

The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location

Ilon Liu, Li Jiang, Erik Samuelsson et al. · Nature Genetics · 2022 · 193 citations · Full text

Medicine, Cell Biology, Oncology +17

A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma

Isabel Arrillaga‐Romany, Joshua E. Allen, Wolfgang Oster et al. · Oncotarget · 2017 · 170 citations · Full text

Medicine, Oncology, Pharmacology +15